
Revenue on track, profit delayed — overhead absorption masks the Q1 story
SteriPort · capacity-delay · overhead-absorption

SteriPort · capacity-delay · overhead-absorption

capacity-delay · polymer-absorption · FY28-targets

cdmo growth · margin expansion · api losses narrowing

acquisition integration · occupancy recovery · CGHS benefit

NATCO Pharma · Revlimid cliff · trough year

IPCA · pharma · Q1 results
pharma · generics · US exports

cdmo growth · margin expansion · capex approval

ayurveda healthcare · product segment growth · operating margin compression

hospital services · margin expansion · healthcare segment

pharma distribution · margin expansion · acquisition led growth

pharma · bulk drugs · margin expansion

healthcare network · margin compression · segment loss

export momentum 46% · pricing power · injectable facility 5% util.

pharma intermediates · api manufacturing · margin expansion

Abbott India · pharma · Q1 FY27

earnings preview · Q1 FY27 · Zydus Lifesciences

hospital · demerger · occupancy

crdmo · pharma cdmo · margin expansion

pharmaceuticals · acquisition integration · tax normalization

diagnostics · margin expansion · pat growth

pharmaceuticals · margin compression · employee costs

oncology hospitals · margin expansion · npm improvement

specialty chemicals · pharma segment · crop protection

pharmaceuticals · margin expansion · tax credit

pharmaceuticals · one-off gain · asset sale

pharmaceuticals · generics · eu gmp

pharma exports · margin expansion · international revenue growth

clinical stage biopharma · phase 3 trial · r&d expense surge